Risk of foreign API manufacturers entering the Japanese market
First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2018.
The whole theme swung hardest in 2026: 31 of 91 companies on the "Worse" side.
- FY2018RestatedAnnual report
「Large foreign manufacturers of active pharmaceutical ingredient bulk products may seek to enter the Japanese market in the future by acquiring Japanese companies or through other means, and if the number of such overseas companies increases, the Group’s operating results and other aspects of its performance may be affected.」
The risk of intensifying competition as foreign API manufacturers enter the Japanese market has been reiterated. - FY2017RestatedAnnual report
「Large foreign manufacturers of active pharmaceutical ingredient bulk products may seek to enter the Japanese market in the future by acquiring Japanese companies or through other means, and if the number of such overseas companies increases, the Group’s operating results and other aspects of its performance may be affected.」
The risk of intensifying competition as foreign API manufacturers enter the Japanese market has been reiterated. - FY2016First statedAnnual report
「Large foreign manufacturers of active pharmaceutical ingredient bulk products may seek to enter the Japanese market in the future by acquiring Japanese companies or through other means, and if the number of such overseas companies increases,」
The company recognizes its advantage in meeting Japanese quality standards while describing the potential for intensifying competition.